Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws, specifically regarding misleading statements about the company's financial status and operational funding [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Zenas to contact them for discussing legal options [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [2][4]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [4]. Group 2: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to contact the firm [6]. - For more information about the class action, interested parties can visit the firm's website or contact the partner directly [7].
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma